Molecular biomarkers in neurocritical care: The next frontier

Keyphrases

• Molecular Biomarkers 100%
• Neurocritical Care 100%
• Clinical Trials 50%
• Quality of Life 50%
• Clinical Practice 50%
• Central Nervous System 50%
• Diagnostic Interventions 50%
• Pathophysiology 50%
• Blood-brain Barrier 50%
• Tissue Sampling 50%
• Disease Progression 50%
• Personalized Medicine 50%
• Brain Tissue 50%
• Clinical Disease 50%
• Myocardial Infarction 50%
• Therapeutic Treatment 50%
• Critical Care 50%
• Critical Care Medicine 50%
• Modern Medicine 50%
• Tumor Marker 50%
• Neurological Injury 50%
• Patient Selection 50%
• Life Support 50%
• Chronic Myeloid Leukemia 50%
• Critical Illness 50%
• Prognostic Accuracy 50%
• Resuscitation 50%
• Holy Grail 50%
• New Disease 50%
• Troponin 50%
• Skull 50%
• Imatinib 50%
• Intermediate Phenotype 50%
• Gleevec 50%
• Brain Monitoring 50%

Medicine and Dentistry

• Biological Marker 100%
• Imatinib 100%
• Medicine 100%
• Diseases 100%
• Disease Exacerbation 50%
• Myocardial Infarction 50%
• Pathophysiology 50%
• Intensive Care 50%
• Tumor Marker 50%
• Chronic Myelogenous Leukemia 50%
• Blood Brain Barrier 50%
• Critical Illness 50%
• Central Nervous System 50%
• Neuromonitoring 50%
• Tissue Sampling 50%
• Clinical Trial 50%
• Quality of Life 50%
• Brain Tissue 50%
• Intensive Care Medicine 50%
• Troponin 50%
• Resuscitation 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Imatinib 100%
• Diseases 100%
• Clinical Trial 50%
• Heart Infarction 50%
• Disease Exacerbation 50%
• Chronic Myeloid Leukemia 50%
• Critical Illness 50%
• Pathophysiology 50%
• Tumor Marker 50%
• Troponin 50%
• Blood-Brain Barrier 50%